TriMix DC

Drug Profile

TriMix DC

Alternative Names: TriMixDC

Latest Information Update: 27 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator eTheRNA Immunotherapies
  • Developer Vrije Universiteit Brussel
  • Class Cancer vaccines; Cell therapies; Immunotherapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Dendritic cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Malignant melanoma; Multiple myeloma

Most Recent Events

  • 27 Jul 2017 Vrije Universiteit Brussel has patent protection for TriMiX technology in USA and Europe
  • 12 Jul 2017 TriMix-DC is available for licensing as of 12 Jul 2017. (eTheRNA website, July 2017)
  • 12 Jul 2017 Suspended - Phase-II for Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in Belgium (Intradermal) (IV) (eTheRNA website, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top